Publications by authors named "C Falciani"
Article Synopsis
- Immunogenic cell death (ICD) offers a new avenue for treating non-immunoreactive tumors that typically resist standard therapies.
- The study focused on two new oncolytic peptides, BOP7 and BOP9, which selectively killed pancreatic cancer cells while sparing non-tumor cells, attributed to their ability to bind to specific molecules on cancer cells.
- BOPs not only showed promising tumor-specific cytotoxicity, triggering the release of pro-inflammatory signals (DAMPs), but also demonstrated anti-metastatic properties and effectiveness in reducing tumor growth in a mouse model of pancreatic cancer.
Article Synopsis
- * A selection of six branched peptides, designed to improve resistance to proteases and boost efficacy, was tested for antibacterial activity, biofilm inhibition, cytotoxicity, and resistance to breakdown.
- * The peptide BAMP2 demonstrated encouraging results in treating mouse skin infections, suggesting its potential for local application in infection management.
, a pathogen capable of causing diseases ranging from mild to life-threatening, has a large arsenal of virulence factors. Notably, extracellular vesicles have emerged as significant players in the pathogenesis of this organism. However, the full range of their functions is still being studied, and difficulties related to vesicle purification (long protocols, low yields, and specialized instruments) have become a major obstacle for their characterization.
View Article and Find Full Text PDFAim: To investigate the bidirectional influence between periodontitis and psoriasis, using the respective experimental models of ligature- and imiquimod-induced diseases on murine models.
Materials And Methods: Thirty-two C57/BL6J mice were randomly allocated to four experimental groups: control (P- Pso-), ligature-induced periodontitis (P+ Pso-), imiquimod-induced psoriasis (P- Pso+) and periodontitis and psoriasis (P+ Pso+). Samples (maxilla, dorsal skin and blood) were harvested immediately after death.
SET-M33 is a synthetic peptide that is being developed as a new antibiotic against major Gram-negative bacteria. Here we report two in vivo studies to assess the toxicity and efficacy of the peptide in a murine model of pulmonary inflammation. First, we present the toxicity study in which SET-M33 was administered to CD-1 mice by snout inhalation exposure for 1 h/day for 7 days at doses of 5 and 20 mg/kg/day.
View Article and Find Full Text PDF